Outcomes Data Remain “Weapon” Against Risk-Averse Environment For J&J
Disappointing regulatory outcomes in 2005 and the current risk-averse policy environment have negatively impacted Johnson & Johnson's outlook for 2006, CEO William Weldon said during a financial presentation Jan. 24
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth